Epirubicin + cisplatin + capecitabine

Epirubicin + cisplatin + capecitabine (ECX) is a combination chemotherapy regimen used primarily for the treatment of advanced or operable cancers of the stomach (gastric cancer), esophagus (oesophageal cancer), and gastroesophageal junction. - **Epirubicin** is an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II, leading to inhibition of DNA replication and transcription. - **Cisplatin** is a platinum-based compound that forms DNA crosslinks, causing apoptosis by inhibiting DNA synthesis and function[6]. - **Capecitabine** is an oral prodrug converted to 5-fluorouracil (5-FU) in the body; it inhibits thymidylate synthase, disrupting DNA synthesis in rapidly dividing cells. The combination works synergistically to destroy rapidly dividing cancer cells through multiple mechanisms affecting DNA structure and function. The regimen typically involves intravenous administration of epirubicin and cisplatin with oral capecitabine taken daily for 21 days per cycle[1][2][4][8].

Other names

epirubicincisplatincapecitabineECX regimen